Progress in research on hepatitis C virus infection in kidney transplant recipients

doi:10.3877/cma.j.issn.1674-3903.2023.01.009

Abstract

Abstract:

Hepatitis C virus infection is highly prevalent in kidney transplant recipients and is one of the major risk factors for postoperative complications, transplant kidney survival and recipient prognosis. Recent studies have shown that the use of direct-acting antiviral agents(DAAs) in kidney transplant recipients is effective in improving prognosis, reducing the risk of postoperative complications and increasing the survival rate of the transplanted kidney, and has been beneficial in the exploratory treatment of hepatitis C virus-positive donor kidney transplants, but more evidence from high-quality trials and evidence-based medicine is still needed. This review provides an overview of research advances in hepatitis C virus infection and kidney disease, post-transplant complications, post-operative DAAs therapy and the use of hepatitis C virus-positive donor kidneys.

Key words: Hepatitis C virus, Kidney transplantation, Direct-acting antiviral agents

Na Li, Dan Wang. Progress in research on hepatitis C virus infection in kidney transplant recipients[J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(01): 58-62.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2023.01.009

https://zhyzzz.cma-cmc.com.cn/EN/Y2023/V17/I01/58

References 55

1	中华医学会感染病学分会，中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华肝脏病杂志，2019，27(12)：938-961.
2	Sawinski D, Blumberg EA. Infection in renal transplant recipients[M]//Himmelfarb Jonathan, Ikizler T. Alp. Chronic kidney disease, dialysis, and transplantation (4 edition). Philadelphia: Elsevier, 2019.
3	Morales JM, Fabrizi F. Hepatitis C and its impact on renal transplantation[J]. Nat Rev Nephrol, 2015, 11(3): 172-182.
4	Morales JM, Campistol JM. Transplantation in the patient with hepatitis C[J]. J Am Soc Nephrol, 2000, 11(7): 1343-1353.
5	Daloul R, Pesavento TE, Goldberg DS, et al. A review of kidney transplantation from HCV-viremic donors into HCV-negative recipients[J]. Kidney Int, 2021, 100(6): 1190-1198.
6	Zhang J, Sun W, Lin J, et al. Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China[J]. BMC Infect Dis, 2019, 19(1): 1-6.
7	Reddy YNV, Nunes D, Chitalia V, et al. Hepatitis C virus infection in kidney transplantation‐changing paradigms with novel agents[J]. Hemodial Int, 2018, 22(Suppl 1): S53-S60.
8	Lai TS, Lee MH, Yang HI, et al. Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study[J]. Hepatology, 2017, 66(3): 784-793.
9	Park H, Adeyemi A, Henry L, et al. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection[J]. J Viral Hepat, 2015, 22(11): 897-905.
10	Somerville L, Doucette K. Hepatitis C: current controversies and future potential in solid organ transplantation[J]. Curr Infect Dis Rep, 2018, 20(7): 1-10.
11	Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies[J]. World J Gastroenterol, 2014, 20(24): 7544-7554.
12	Pol S, Parlati L, Jadoul M. Hepatitis C virus and the kidney[J]. Nat Rev Nephrol, 2019, 15(2): 73-86.
13	Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States[J]. Am J Kidney Dis, 2019, 75(1 Suppl 1)：A6-A7.
14	Cohen-Bucay A, Gordon CE, Francis JM. Non-immunological complications following kidney transplantation[J]. F1000Res, 2019, 8：F1000 Faculty Rev-194.
15	Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis[J]. Lancet Glob Health, 2016, 4(9): e609-e616.
16	Nakano T, Ninomiya T, Sumiyoshi S, et al. Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study[J]. Am J Kidney Dis, 2010, 55(1): 21-30.
17	Lentine KL, Costa SP, Weir MR, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation[J]. J Am Coll Cardiol, 2012, 60(5): 434-480.
18	European Renal Best Practice Transplantation Guideline Development Group. ERBP guideline on the management and evaluation of the kidney donor and recipient[J]. Nephrol Dial Transplant, 2013, 28 Suppl 2: ii1-71.
19	Ramphul R, Fernandez M, Firoozi S, et al. Assessing cardiovascular risk in chronic kidney disease patients prior to kidney transplantation: clinical usefulness of a standardised cardiovascular assessment protocol[J]. BMC Nephrol, 2018, 19(1): 1-12.
20	Weiner DE, Park M, Tighiouart H, et al. Albuminuria and allograft failure, cardiovascular disease events, and all-cause death in stable kidney transplant recipients: a cohort analysis of the FAVORIT trial[J]. Am J Kidney Dis, 2019, 73(1): 51-61.
21	Li S, Wang J, Zhang B, et al. Diabetes mellitus and cause-specific mortality: a population-based study[J]. Diabetes Metab J, 2019, 43(3): 319-341.
22	Fabrizi F, Martin P, Dixit V, et al. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies[J]. Am J Transplant, 2005, 5(10): 2433-2440.
23	Santos AH Jr, Chen C, Casey MJ, et al. New-onset diabetes after kidney transplantation: can the risk be modified by choosing immunosuppression regimen based on pretransplant viral serology？[J]. Nephrol Dial Transplant, 2018, 33(1): 177-184.
24	Jeon HJ, Bae HJ, Ham YR, et al. Outcomes of end-stage renal disease patients on the waiting list for deceased donor kidney transplantation: a single-center study[J]. Kidney Res Clin Pract, 2019, 38(1): 116-123.
25	Fabiani S, Fallahi P, Ferrari SM, et al. Hepatitis C virus infection and development of type 2 diabetes mellitus: systematic review and meta-analysis of the literature[J]. Rev Endocr Metab Disord, 2018, 19(4): 405-420.
26	Ponticelli C, Favi E, Ferraresso M. New-Onset diabetes after kidney transplantation[J]. Medicina (Kaunas), 2021, 57(3): 250.
27	Rodrigo E, de Cos MA, Fernández-Fresnedo G, et al. Higher initial tacrolimus blood levels and concentration-dose ratios in kidney transplant recipients who develop diabetes mellitus. Transplantation proceedings[J]. Transplant Proc, 2005, 37(9): 3819-3820.
28	Liang J, Lv C, Chen M, et al. Effects of preoperative hepatitis B virus infection, hepatitis C virus infection, and coinfection on the development of new-onset diabetes after kidney transplantation[J]. J Diabetes, 2019, 11(5): 370-378.
29	Chiu KC, Lee NP, Cohan P, et al. Beta cell function declines with age in glucose tolerant Caucasians[J]. Clin Endocrinol (Oxf), 2000, 53(5): 569-575.
30	Ma Y, Yan WW. Chronic hepatitis C virus infection and post-liver transplantation diabetes mellitus[J]. World J Gastroenterol, 2005, 11(39): 6085-6089.
31	Lin MV, Sise ME, Pavlakis M, et al. Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection[J]. PLoS One, 2016, 11(7): e0158431.
32	Durand C, Brown D, Wesson R, et al. EXPANDER-1: exploring renal transplants using hepatitis-C infected donors for HCV-negative recipients[C]. Am J Transplant, 2017, 17: 207.
33	Goldberg DS, Abt PL, Reese PP; THINKER Trial Investigators. Transplanting HCV-infected kidneys into uninfected recipients[J]. N Engl J Med, 2017, 377(11): 1105.
34	Eisenberger U, Guberina H, Willuweit K, et al. Successful treatment of chronic hepatitis C virus infection with sofosbuvir and ledipasvir in renal transplant recipients[J]. Transplantation, 2017, 101(5): 980-986.
35	Kamar N, Marion O, Rostaing L, et al. Efficacy and safety of sofosbuvir‐based antiviral therapy to treat hepatitis C virus infection after kidney transplantation[J]. Am J Transplant, 2016, 16(5): 1474-1479.
36	Fabrizi F, Alonso C, Palazzo A, et al. 'Real-life’experience with direct-acting antiviral agents for HCV after kidney transplant[J]. Ann Hepatol, 2021, 25: 100337.
37	Devresse A, Delire B, Lazarus JV, et al. Eliminating hepatitis C virus from a prevalent kidney transplant recipient population: a single-center study in Belgium in the direct-acting antivirals era[J]. Transplant Proc, 2020, 52(3): 815-822.
38	European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69(2)：461-511.
39	Dashti-Khavidaki S, Khalili H, Nasiri-Toosi M. Potential nephrotoxicity of sofosbuvir-based treatment in patients infected with hepatitis C virus: a review on incidence, type and risk factors[J]. Expert Rev Clin Pharmacol, 2018, 11(5): 525-529.
40	Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection[J]. Hepatology, 2020, 71(2): 686-721.
41	De A, Roy A, Verma N, et al. Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: a systematic review and meta-analysis[J]. Nephrology, 2022, 27(1): 82-89.
42	Ladino M, Pedraza F, Roth D. Hepatitis C virus infection in chronic kidney disease[J]. J Am Soc Nephrol, 2016, 27(8): 2238-2246.
43	Mendizabal M, Reddy KR. Chronic hepatitis C and chronic kidney disease: advances, limitations and unchartered territories[J]. J Viral Hepat, 2017, 24(6): 442-453.
44	El Helou G, Jay C, Nunez M. Hepatitis C virus and kidney transplantation: recent trends and paradigm shifts[J]. Transplant Rev (Orlando), 2022, 36(1)：100677.
45	Czarnecka P, Czarnecka K, Tronina O, et al. Utilization of HCV viremic donors in kidney transplantation: a chance or a threat？[J]. Ren Fail, 2022, 44(1): 434-449.
46	Feng Z, Zhang J, Tan W, et al. Efficacy and safety of direct-acting antivirals in kidney transplantation from HCV-viremic donors to negative recipients: a meta-analysis[J]. Front Med (Lausanne), 2022, 9：802686.
47	Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial[J]. Ann Intern Med, 2018, 168(8): 533-540.
48	Chen R, Li D, Zhang M, et al. Sofosbuvir/Velpatasvir prophylaxis for 12 weeks in hepatitis C virus (HCV)-negative recipients receiving kidney transplantation from HCV-positive donors[J]. Ann Transplant, 2021, 26: e933313-1.
49	冯成，杨洪吉，侯一夫，等. 直接抗病毒药物在肾移植丙型肝炎病毒患者中的应用[J/CD]. 实用器官移植电子杂志，2020, 8(2): 96-100.
50	Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease[J]. Gastroenterology, 2016, 150(7): 1590-1598.
51	Kahn JA. The use of organs from hepatitis C virus-viremic donors into uninfected recipients[J]. Curr Opin Organ Transplant, 2020, 25(6): 620-625.
52	King KL, Husain SA, Mohan S. Trends in transplantation center use of kidneys from deceased donors with positive hepatitis C virus nucleic acid testing[J]. Am J Kidney Dis, 2020, 76(5): 743-746.
53	Wang JH, Gustafson SK, Skeans MA, et al. OPTN/SRTR 2018 Annual Data Report: Hepatitis C[J]. Am J Transplant, 2020, 20 Suppl s1: 542-568.
54	Coppola N, Minichini C, Starace M, et al. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals[J]. J Med Virol, 2016, 88(10): 1659-1671.
55	Knoll GA, Tankersley MR, Lee JY, et al. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients[J]. Am J Kidney Dis, 1997, 29(4): 608-614.

[1]	Branch of Organ Transplant of Chinese Medical Association, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association, Shanghai Pharmaceutical Profession Association. Expert Consensus on the Use of Mycophenolic Acid in Chinese Liver and Kidney Transplant Recipients (2023 edition) [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 257-272.
[2]	Weifang Zhu, Lin Chen, Jianjun Qiao. Laser combined with photodynamic therapy in the treatment of bowenoid papulosis after kidney transplantation recipient: a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(04): 250-252.
[3]	Ruochen Qi, Shuaijun Ma, Shichao Han, Guohui Wang, Kepu Liu, Xiaoyan Zhang, Xiaojian Yang, Weijun Qin. Diagnosis and treatment of COVID-19 in kidney transplant recipients: experience from a single center [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(04): 232-239.
[4]	Qi Chen, Jiayu Guo, Zhongbao Chen, Xiaoxiong Ma, Tianyu Wang, Jilin Zou, Long Zhang, Zhitao Cai, Tao Qiu, Jiangqiao Zhou. Combined heart and kidney transplantation: a report of 3 cases [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(02): 124-127.
[5]	Xiuyuan Zhang, Junhao Lyu, Dajin Chen. Research progress of kidney transplantation in 2022 [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(01): 32-35.
[6]	Chenchen Zhu, Fei Han, Zhangfei Shou. Kidney transplantation from HCV-positive donors: a single-center experience [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(01): 47-53.
[7]	Shaohua Shi, Xinglong Yue, Lijun Zhu, Xiaotong Wu. Plasma cell-rich acute rejection in transplanted kidney: a case report and literature review [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(06): 373-375.
[8]	Hongbing Wu, Zhiwei Wang, Luocheng Li, Zongli Ren, Junxia Hu, Peng Song, Yongle Ruan. Clinical experience of combined heart and kidney transplantation in the treatment of simultaneous end-stage cardiac and renal dysfunction: two cases [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(06): 369-372.
[9]	Wenbo Yang, Shicong Lai, Xiaopeng Zhang, Zixiong Huang, Weiyu Zhang, Jian Zhang, Rumei Bi, Tao Yu, Qiang Wang. Application of recipient internal iliac artery carrel patch in artery reconstruction during pediatric kidney transplantation: 12 cases [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(06): 365-368.
[10]	Na Li, Xiaoming Ding, Chenguang Ding, Dan Wang. The application of sofosbuvir plus ledipasvir antiviral therapy for HCV infection after renal transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(06): 359-364.
[11]	Luhao Liu, Guojun Li, Yunyi Xiong, Rongxin Chen, Wei Yin, Lei Zhang, Guanghui Li, Jiali Fang, Junjie Ma, Zheng Chen. Predictive value of donor-derived cell-free DNA in simultaneous pancreas-kidney transplantation recipients with acute rejection [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(06): 353-358.
[12]	Mounia Lalouly, Xianghui Wang, Peijun Zhou, Kun Shao, Huimin An, Quan Zhou. Role of dynamic monitoring of T cell subsets absolute counts in predicting infection in renal allograft recipients [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(04): 210-215.
[13]	Yiting Liu, Tao Qiu, Zhongbao Chen, Xiaoxiong Ma, Tianyu Wang, Long Zhang, Jilin Zou, Zeya Jin, Yu Xu, Jiangqiao Zhou. Effects of donor kidneys with acute kidney injury on the prognosis of recipients after kidney transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(03): 140-146.
[14]	Cheng Qiu, Shuai Dai, Lexi Zhang, Hongtao Liu. Effect of initial blood group antibody titer on renal function and immune function in ABO blood type-incompatible live renal transplant receptors [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(10): 1005-1011.
[15]	Xiaoning Liang, Chaoyang Lv, Ruijun Guo. Application of bedside ultrasound in simultaneous pancreas-kidney transplantation for type I diabetes mellitus [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(06): 553-557.

Please choose a citation manager

Content to export